289
Participants
Start Date
December 31, 2011
Primary Completion Date
May 31, 2013
Study Completion Date
September 30, 2013
CaPre™
1 capsule of 0.5g total CaPre™ for 4 weeks followed by one 1.0g capsule per day for an additional 4 weeks
CaPre™
1 capsule of 1.0g total CaPre™ for 4 weeks followed by two 1.0g capsules per day for an additional 4 weeks
CaPre™
2 capsules of 1.0g total CaPre™ for 4 weeks followed by 4 capsules of 1.0g total per day for an additional 4 weeks.
Lipid Lowering Medication
Patient will be treated as per the Standard of care.
CaPre™
4 capsules of 1 g total per day for 8 weeks.
Alberta Health Services Clinical Trials, Red Deer
Abbotsford
Kelowna
BC Diabetes, Vancouver
Victoria
Winnipeg
Dieppe
Entralogix Clinical Research, Aurora
Entralogix Clinical Research, Brampton
Cambridge Cardiac Care Center, Cambridge
Thamesview Ctr of Family Med, Chatam
Moran Medical Centre, Colingwood
C & L Research, Fort Erie
G.S. Cardiac Lab Medicine Professional Corp, Greater Sudbury
Hamilton
Entralogix Clinical Research, Kitchener
Entralogix Clinical Research, Mississauga
Malton Medical Research Group, Mississauga
Niagara Falls
Entralogix Clinical Research, North York
Taunton Health Centre, Oshawa
Steeple Hill Medical centre, Pickering
Entralogix Clinical Research, Toronto
Eric Silver Medicine Professional Corporation, Toronto
Clinique Médicale des Trois Lacs, Vaudreuil Dorion
Clinique Medicale Valcartier, Courcelette
Clinique Reseau le Trait d'Union, Delson
Clinique Medicale Mistassini, Dolbeau-Mistassini
Clinique medicale, Grand-Mère
GMF Grand Mere, Grand-Mère
CRM Lanaudiere, Joliette
Applied Medical Information Research AMIR, Montreal
Centre de recherche A&E, Québec
Clinique des maladies lipidiques de Quebec Inc., Québec
Clinique Services Sante Rosemere, Rosemère
Csss de St-Jerome, Saint-Jérôme
CSSS Vallee De L'Or, Val-d'Or
Applied Medical Information Research (AMIR), Westmount
Lead Sponsor
Collaborators (1)
JSS Medical Research Inc.
INDUSTRY
Grace Therapeutics Inc.
INDUSTRY